Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Attachment |
| Title | PubMed entry |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/30944458 |
| Accessed | 2019/04/16 - 18:33:19 |
| Date Added | 2019/04/16 - 16:33:19 |
| Date Modified | 2019/04/16 - 16:33:19 |
| Parent item | Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de